While the life sciences industry works to heal the world, its own environmental footprint tells a sobering story: responsible for 4.4% of global industrial emissions, the sector is now in a transformative race where giants like Pfizer have slashed manufacturing emissions by 46% and companies like Bristol Myers Squibb are already powered by 100% renewable electricity.
Key Takeaways
- In 2022, the global pharmaceutical industry accounted for approximately 4.4% of total greenhouse gas emissions from all industrial sectors, equating to around 78 million metric tons of CO2 equivalent from manufacturing alone
- Pfizer reported a 46% reduction in Scope 1 and 2 GHG emissions per API kg produced from 2017 to 2022 baseline, achieving 0.12 tCO2e per kg API
- Novartis achieved a 25% absolute reduction in Scope 1 and 2 emissions by 2022 compared to 2016, totaling 145,000 tCO2e
- The pharmaceutical industry generated 250,000 tons of hazardous waste annually in the EU in 2021, with 70% incinerated
- Pfizer diverted 99% of non-hazardous waste from landfill in 2022 across global sites
- Novartis recycled or reused 85% of total waste generated in 2022, totaling 45,000 tons diverted
- Global pharma industry used 2.8 billion cubic meters of water in 2021, with biotech at 15% higher intensity
- Pfizer reduced freshwater withdrawal by 25% per ton product from 2017-2022
- Novartis cut absolute water use by 18% since 2016, to 12 million m3 in 2022
- 85% of pharma supply chain emissions stem from active pharmaceutical ingredients (APIs) sourcing from China and India in 2022
- Pfizer audited 95% Tier 1 suppliers for sustainability in 2022
- Novartis sourced 60% of palm oil RSPO-certified in 2022 for excipients
- 72% of biopharma companies have net-zero targets aligned with SBTi as of 2023
- EU pharma industry complies with 95% of ELV Directive recycling quotas in 2022
- Pfizer invested $100M in green chemistry R&D for sustainable APIs in 2022
Leading pharmaceutical companies are significantly reducing their carbon emissions, waste, and water use.
Emissions and Energy
1In 2022, the global pharmaceutical industry accounted for approximately 4.4% of total greenhouse gas emissions from all industrial sectors, equating to around 78 million metric tons of CO2 equivalent from manufacturing alone
Verified2Pfizer reported a 46% reduction in Scope 1 and 2 GHG emissions per API kg produced from 2017 to 2022 baseline, achieving 0.12 tCO2e per kg API
Verified3Novartis achieved a 25% absolute reduction in Scope 1 and 2 emissions by 2022 compared to 2016, totaling 145,000 tCO2e
Verified4The life sciences sector's energy intensity stood at 1.2 MWh per million USD revenue in 2021, 20% higher than chemical industry average
Directional5Roche reduced energy consumption by 15% per FTE from 2018-2022, saving 50 GWh annually
Single source6AstraZeneca's Scope 3 emissions from purchased goods represent 78% of total footprint, at 2.1 million tCO2e in 2022
Verified7Sanofi cut Scope 1 emissions by 52% since 2019 baseline, reaching 45,000 tCO2e in 2022
Verified8Global biopharma manufacturing emitted 52 MtCO2e from direct operations in 2020, per WEF report
Verified9Merck & Co. achieved 30% renewable energy usage in 2022, up from 12% in 2015, powering 45% of sites
Directional10GSK reported 22% reduction in GHG emissions intensity per product value since 2020
Single source11Johnson & Johnson reduced absolute Scope 1 and 2 emissions by 18% from 2018-2022, to 320,000 tCO2e
Verified12Eli Lilly's energy use efficiency improved by 28% per manufacturing output from 2015-2022
Verified13Biogen sourced 100% renewable electricity for US operations in 2022, reducing emissions by 25,000 tCO2e
Verified14Amgen decreased GHG intensity by 35% since 2015, achieving 0.08 tCO2e per thousand USD revenue
Directional15Regeneron Pharmaceuticals cut Scope 1 emissions 40% per sqm facility space by 2022
Single source16Vertex Pharmaceuticals achieved 50% renewable energy procurement by 2023
Verified17Gilead Sciences reported 15% drop in energy use per R&D FTE from 2019-2022
Verified18Moderna increased renewable energy to 20% of total consumption in 2022, targeting 100% by 2030
Verified19AbbVie reduced Scope 2 emissions by 60% through RE procurement, to 120,000 tCO2e in 2022
Directional20Bristol Myers Squibb hit 100% renewable electricity globally in 2022
Single source21Takeda lowered GHG emissions 20% per sales unit since 2020 baseline
Verified22CSL Behring achieved 25% energy efficiency gain in manufacturing by 2022
Verified23Thermo Fisher Scientific reported 18% Scope 1+2 reduction per revenue since 2018
Verified24Danaher cut emissions intensity 22% from 2019-2022 across life sciences portfolio
Directional25Illumina reduced facility energy use by 30% per sq ft since 2015
Single source26Agilent Technologies sourced 45% renewable energy in 2022, up 15% YoY
Verified27Waters Corporation achieved carbon neutral manufacturing sites by 2022
Verified28PerkinElmer (Revvity) lowered Scope 3 emissions 12% through supplier engagement in 2022
Verified29Sigma-Aldrich (Merck KGaA) recycled 92% of manufacturing waste, reducing emissions equivalent
Directional30Lonza Group reduced energy per ton product by 18% from 2016-2022
Single sourceEmissions and Energy Interpretation
While celebrating the industry's impressive individual strides towards efficiency and renewables, the sobering reality remains that pharmaceutical manufacturing is still a major global emitter, with its outsized upstream supply chain emissions posing the next monumental challenge to truly heal its climate footprint.
Regulatory and Innovation
172% of biopharma companies have net-zero targets aligned with SBTi as of 2023
Verified2EU pharma industry complies with 95% of ELV Directive recycling quotas in 2022
Verified3Pfizer invested $100M in green chemistry R&D for sustainable APIs in 2022
Verified4Novartis launched 15 biocatalytic processes reducing waste by 50% each in 2022
Directional5Roche patented 20 continuous manufacturing tech for lower emissions by 2022
Single source6AstraZeneca developed solvent-free formulations cutting VOC emissions 40% in 2022
Verified7Sanofi achieved 100% compliance with REACH regulations across EU sites in 2022
Verified8Merck & Co. filed 30 green patents for biotech processes in 2022
Verified9GSK innovated 100% biodegradable inhaler components by 2022
Directional10Johnson & Johnson met 100% GRI standards disclosure for sustainability in 2022
Single source11Eli Lilly implemented AI for 25% energy optimization in labs by 2022
Verified12Biogen scaled mRNA platform with 30% less resource use per dose in 2022
Verified13Amgen deployed modular bioreactors reducing water 20% per batch in 2022
Verified14Regeneron achieved FDA recognition for sustainable manufacturing pilot in 2022
Directional15Vertex invested $50M in gene therapy green production tech in 2022
Single source16Gilead launched CAR-T process with 40% emissions cut via innovation in 2022
Verified17Moderna adopted digital twins for 15% process efficiency gains in 2022
Verified18AbbVie complied with 100% TCFD recommendations in disclosures 2022
Verified19Bristol Myers Squibb developed solvent recycling tech recovering 90% in 2022
Directional20Takeda filed 18 patents for microbiome sustainable culturing in 2022
Single source21CSL innovated plasma fractionation with 25% energy reduction tech in 2022
Verified22Thermo Fisher launched 50 green lab products reducing waste 30% in 2022
Verified23Danaher patented flow chemistry for 35% yield improvement sustainably in 2022
Verified24Illumina advanced NGS with 20% lower energy sequencing chips in 2022
Directional25Agilent introduced GC-MS with 50% solvent reduction innovation in 2022
Single source26Waters developed eco-mode LC systems saving 40% water per analysis in 2022
Verified27Revvity achieved ISO 14001 certification at 95% sites in 2022
Verified28Merck KGaA launched BioReliance green validation services in 2022
Verified29Lonza scaled E.coli-free protein production cutting emissions 28% in 2022
DirectionalRegulatory and Innovation Interpretation
It appears the life science industry has finally prescribed itself a strong dose of planet-saving ambition, shifting from merely treating patients to actively healing its own environmental footprint through a rigorous regimen of net-zero targets, green chemistry, and waste-slashing innovations.
Supply Chain Sustainability
185% of pharma supply chain emissions stem from active pharmaceutical ingredients (APIs) sourcing from China and India in 2022
Verified2Pfizer audited 95% Tier 1 suppliers for sustainability in 2022
Verified3Novartis sourced 60% of palm oil RSPO-certified in 2022 for excipients
Verified4Roche engaged 80% suppliers in CDP supply chain program by 2022
Directional5AstraZeneca committed 100% sustainable palm derivatives by 2023
Single source6Sanofi verified 90% API suppliers for environmental compliance in 2022
Verified7Merck & Co. reduced Scope 3 Category 1 emissions by 15% through supplier efficiency
Verified8GSK mapped 100% Tier 1 suppliers for deforestation risk in 2022
Verified9Johnson & Johnson sourced 75% responsible minerals in devices by 2022
Directional10Eli Lilly achieved 70% supplier sustainability assessments completed in 2022
Single source11Biogen used 50% recycled plastics in packaging from sustainable sources in 2022
Verified12Amgen audited 85% critical suppliers for ESG risks in 2022
Verified13Regeneron shifted 20% API production to greener facilities by 2022
Verified14Vertex sourced 65% renewable attribute certificates for supply energy in 2022
Directional15Gilead improved supplier deforestation-free commodities to 90% coverage in 2022
Single source16Moderna partnered with 40 suppliers for carbon reduction plans in 2022
Verified17AbbVie achieved 88% supplier code adherence rate in 2022 audits
Verified18Bristol Myers Squibb onboarded 100% new suppliers to sustainability platform by 2022
Verified19Takeda sourced 55% APIs from preferred sustainable suppliers in 2022
Directional20CSL verified 92% plasma collection centers for sustainability in 2022
Single source21Thermo Fisher trained 75% suppliers on ESG standards in 2022
Verified22Danaher reduced supply chain plastic use by 15% through alternatives in 2022
Verified23Illumina sourced 80% conflict-free minerals certified in 2022
Verified24Agilent achieved 70% sustainable packaging materials from suppliers by 2022
Directional25Waters mapped 95% Scope 3 emissions from supply chain in 2022
Single source26Revvity engaged 82% suppliers in water stewardship initiatives in 2022
Verified27Merck KGaA sourced 100% traceable palm oil for products in 2022
Verified28Lonza committed to 100% deforestation-free supply chain by 2025, 60% achieved in 2022
VerifiedSupply Chain Sustainability Interpretation
The pharmaceutical industry is finally admitting the cleanest patient starts with a dirty secret: while they're meticulously auditing their immediate suppliers' paper straws, a whopping 85% of their supply chain pollution is embedded in the raw ingredients shipped from across the globe.
Waste and Recycling
1The pharmaceutical industry generated 250,000 tons of hazardous waste annually in the EU in 2021, with 70% incinerated
Verified2Pfizer diverted 99% of non-hazardous waste from landfill in 2022 across global sites
Verified3Novartis recycled or reused 85% of total waste generated in 2022, totaling 45,000 tons diverted
Verified4Roche achieved zero waste to landfill at 90% of sites by 2022, diverting 28,000 tons
Directional5AstraZeneca reduced packaging waste by 25% per product unit from 2018-2022
Single source6Sanofi recycled 82% of operational waste in 2022, avoiding 15,000 tons to landfill
Verified7Merck & Co. attained 95% waste diversion rate globally in 2022
Verified8GSK sent zero manufacturing waste to landfill from 2018 onwards
Verified9Johnson & Johnson recycled 94% of waste in 2022, up from 85% in 2015
Directional10Eli Lilly achieved 90% waste recycling rate in manufacturing by 2022
Single source11Biogen diverted 97% of waste from disposal in 2022
Verified12Amgen reached zero waste to landfill certification at 15 sites in 2022
Verified13Regeneron recycled 88% of total waste volume in 2022
Verified14Vertex achieved 92% waste diversion rate across facilities in 2022
Directional15Gilead reduced waste generation intensity by 20% per revenue since 2019
Single source16Moderna recycled 75% of lab waste in 2022, targeting 90% by 2025
Verified17AbbVie diverted 96% of waste from landfill in 2022
Verified18Bristol Myers Squibb achieved 98% waste recycling/reuse rate in 2022
Verified19Takeda reduced hazardous waste by 30% per ton product since 2018
Directional20CSL recycled 89% of non-hazardous waste globally in 2022
Single source21Thermo Fisher diverted 91% of waste from landfill in 2022
Verified22Danaher achieved 93% global waste diversion rate in 2022
Verified23Illumina recycled 85% of e-waste in 2022
Verified24Agilent reduced solvent waste by 40% through recovery tech in 2022
Directional25Waters attained zero plastic to landfill from packaging by 2022
Single source26Revvity recycled 87% of manufacturing waste in 2022
Verified27Merck KGaA diverted 94% of waste across sites in 2022
Verified28Lonza achieved 88% recycling rate for production waste in 2022
VerifiedWaste and Recycling Interpretation
The life science industry is grappling with a hazardous waste legacy heavy enough to sink a fleet, but its leaders are proving that cleaning up their act—from Pfizer's near-perfect landfill diversion to Takeda's shrinking toxic footprint—is not just a pipedream but a measurable, competitive race toward a circular future.
Water and Resources
1Global pharma industry used 2.8 billion cubic meters of water in 2021, with biotech at 15% higher intensity
Verified2Pfizer reduced freshwater withdrawal by 25% per ton product from 2017-2022
Verified3Novartis cut absolute water use by 18% since 2016, to 12 million m3 in 2022
Verified4Roche recycled 65% of water in high-stress areas by 2022
Directional5AstraZeneca achieved 20% water efficiency gain per manufacturing output since 2020
Single source6Sanofi reduced water intensity by 30% per ton API from 2019 baseline
Verified7Merck & Co. withdrew 15 million m3 water in 2022, 22% less than 2015
Verified8GSK recycled 70% of process water at sites in water-scarce regions in 2022
Verified9Johnson & Johnson cut water use 28% per ton product since 2010
Directional10Eli Lilly achieved zero wastewater discharge to surface water at 80% sites by 2022
Single source11Biogen reduced water use intensity by 35% per revenue from 2015-2022
Verified12Amgen recycled 55% of water in manufacturing processes in 2022
Verified13Regeneron decreased water withdrawal 15% YoY in 2022
Verified14Vertex implemented water reuse at 60% of facilities by 2022
Directional15Gilead achieved 25% reduction in water use per R&D activity since 2019
Single source16Moderna treated 90% of wastewater onsite in 2022
Verified17AbbVie cut water intensity 22% per manufacturing sqm since 2018
Verified18Bristol Myers Squibb reached 100% water stewardship assessment at sites by 2022
Verified19Takeda reduced water use 18% absolute from 2018-2022
Directional20CSL recycled 62% of water at biotech facilities in 2022
Single source21Thermo Fisher withdrew 22 million m3 water, recycling 50% in 2022
Verified22Danaher improved water efficiency 20% across life sciences units since 2019
Verified23Illumina reduced lab water use by 28% per test volume in 2022
Verified24Agilent achieved zero liquid discharge at 10 manufacturing sites by 2022
Directional25Waters recycled 75% of ultrapure water in production in 2022
Single source26Revvity cut water intensity 16% per revenue in 2022
Verified27Merck KGaA reused 68% of process water globally in 2022
Verified28Lonza reduced water per ton cell culture by 25% from 2016-2022
VerifiedWater and Resources Interpretation
The industry’s staggering water footprint reveals a deep-seated paradox—that a sector dedicated to life remains perilously thirsty—but the growing chorus of corporate achievements proves it’s finally learning to treat its own addiction.
Sources & References
- Reference 1MCKINSEYmckinsey.comVisit source
- Reference 2PFIZERpfizer.comVisit source
- Reference 3NOVARTISnovartis.comVisit source
- Reference 4DELOITTEwww2.deloitte.comVisit source
- Reference 5ROCHEroche.comVisit source
- Reference 6ASTRAZENECAastrazeneca.comVisit source
- Reference 7SANOFIsanofi.comVisit source
- Reference 8WEFORUMweforum.orgVisit source
- Reference 9MERCKmerck.comVisit source
- Reference 10GSKgsk.comVisit source
- Reference 11JNJjnj.comVisit source
- Reference 12LILLYlilly.comVisit source
- Reference 13BIOGENbiogen.comVisit source
- Reference 14AMGENamgen.comVisit source
- Reference 15INVESTORinvestor.regeneron.comVisit source
- Reference 16VRTXvrtx.comVisit source
- Reference 17GILEADgilead.comVisit source
- Reference 18INVESTORSinvestors.modernatx.comVisit source
- Reference 19ABBVIEabbvie.comVisit source
- Reference 20BMSbms.comVisit source
- Reference 21TAKEDAtakeda.comVisit source
- Reference 22CSLcsl.comVisit source
- Reference 23IRir.thermofisher.comVisit source
- Reference 24DANAHERdanaher.comVisit source
- Reference 25ILLUMINAillumina.comVisit source
- Reference 26AGILENTagilent.comVisit source
- Reference 27WATERSwaters.comVisit source
- Reference 28CORPORATEcorporate.revvity.comVisit source
- Reference 29SIGMAALDRICHsigmaaldrich.comVisit source
- Reference 30LONZAlonza.comVisit source
- Reference 31ECec.europa.euVisit source
- Reference 32EMDGROUPemdgroup.comVisit source
- Reference 33SCIENCEBASEDTARGETSsciencebasedtargets.orgVisit source
- Reference 34ENVIRONMENTenvironment.ec.europa.euVisit source